Targeted Strategies for Today's Evolving Markets

MissionIR Blog

PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview

  • PaxMedica Chairman and CEO Howard Weisman participated in a recent Bell2Bell Podcast interview and was joined by Buzz Woods from Corporate Communications
  • Weisman discussed the company’s strategy to seek FDA approval for Suramin as a treatment for Human African Trypanosomiasis (“HAT”) and plans for 2024
  • If PaxMedica is successful in getting approval in HAT, the company believes that could lead to the receipt of a Priority Review Voucher (“PRV”)
  • The company hopes to monetize the PRV to raise funds that will support research and future trials investigating Suramin as a treatment for Autism Spectrum Disorder
  • PaxMedica hopes to file an investigational new drug application to use Suramin in a large-scale trial in the U.S. in 2024

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company specializing in innovative treatments for unmet needs in neurodevelopmental disorders, has recently introduced a groundbreaking regulatory strategy that could potentially pave the way for the approval of its lead product candidate, Suramin, in the United States. During a recent episode of the Bell2Bell (“B2B”) Podcast, Chairman and CEO Howard Weisman, along with Buzz Woods from Corporate Communications, delved into this strategy.

To hear the interview, please visit

Suramin, a longstanding treatment for early-stage East African sleeping sickness (Human African Trypanosomiasis or “HAT”), has yet to receive approval for use in the United States for any indication, a gap that PaxMedica aims to bridge. Weisman underscored the crucial link between their regulatory approach for HAT and their overarching mission of addressing Autism Spectrum Disorder (“ASD”), with a specific emphasis on the role of the Investigational New Drug application (“IND”) in facilitating a large-scale study in ASD.

As PaxMedica continues to navigate the complex regulatory landscape, the company remains resolute in its commitment to drive pioneering advancements in neurology and biopharmaceutical research, particularly directed towards addressing the pressing unmet needs in the treatment of neurodevelopmental disorders.

To hear the interview, please visit

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

This entry was posted in PaxMedica Inc. PXMD. Bookmark the permalink.

Comments are closed.